Patients’ characteristics
| Variable . | N, %/median (IQR) . |
|---|---|
| Newly diagnosed | 12 (10) |
| Refractory to previous therapy | 77 (63) |
| Relapsed after previous therapy | 33 (27) |
| Number of prior therapies*, range | 2 (1-3) |
| Previous treatment type* | |
| Alkylating agents | 101 (92) |
| Bortezomib | 69 (63) |
| Lenalidomide/thalidomide | 54 (49)/17 (6) |
| Rituximab/pomalidomide | 21 (19)/8 (7) |
| Other† | 10 (9) |
| Male sex | 76 (62) |
| Age at bendamustine initiation, y | 66 (59-73) |
| Organ involvement | |
| Heart/kidney | 68 (55)/66 (54) |
| Soft tissues/liver | 42 (34)/22 (18) |
| PNS/ANS | 30 (24)/19 (15) |
| GI tract/other‡ | 26 (21)/5 (4) |
| Two or more organs involved | 77 (63) |
| New York Heart Association class III | 36 (29) |
| Cardiac stage18 (evaluable in 95 patients): I/II/III | 23 (24)/52 (54)/20 (21) |
| Renal stage13(evaluable in 104 patients) | |
| I/II/III | 43 (42)/39 (38)/20 (19) |
| Patients on dialysis at BeP initiation | 8 (3) |
| Bone marrow infiltration, % | 15 (8-20) |
| IgM-AL amyloidosis | 36 (29) |
| dFLC, mg/L | 136 (43-429) |
| dFLC >50 mg/L/dFLC >20 mg/L | 68 (53%)/98 (82%) |
| Lambda:kappa | 75 (61):47 (39) |
| Monoclonal component type | |
| IgG/IgM | 33 (27)/36 (29) |
| IgA/light chain only | 8 (6)/45 (38) |
| Bendamustine dosage | |
| 60 mg/m2 | 21 (17) |
| 70 mg/m2 | 11 (9) |
| 80 mg/m2 | 7 (6) |
| 90 mg/m2 | 29 (24) |
| 100 mg/m2 | 54 (44) |
| Variable . | N, %/median (IQR) . |
|---|---|
| Newly diagnosed | 12 (10) |
| Refractory to previous therapy | 77 (63) |
| Relapsed after previous therapy | 33 (27) |
| Number of prior therapies*, range | 2 (1-3) |
| Previous treatment type* | |
| Alkylating agents | 101 (92) |
| Bortezomib | 69 (63) |
| Lenalidomide/thalidomide | 54 (49)/17 (6) |
| Rituximab/pomalidomide | 21 (19)/8 (7) |
| Other† | 10 (9) |
| Male sex | 76 (62) |
| Age at bendamustine initiation, y | 66 (59-73) |
| Organ involvement | |
| Heart/kidney | 68 (55)/66 (54) |
| Soft tissues/liver | 42 (34)/22 (18) |
| PNS/ANS | 30 (24)/19 (15) |
| GI tract/other‡ | 26 (21)/5 (4) |
| Two or more organs involved | 77 (63) |
| New York Heart Association class III | 36 (29) |
| Cardiac stage18 (evaluable in 95 patients): I/II/III | 23 (24)/52 (54)/20 (21) |
| Renal stage13(evaluable in 104 patients) | |
| I/II/III | 43 (42)/39 (38)/20 (19) |
| Patients on dialysis at BeP initiation | 8 (3) |
| Bone marrow infiltration, % | 15 (8-20) |
| IgM-AL amyloidosis | 36 (29) |
| dFLC, mg/L | 136 (43-429) |
| dFLC >50 mg/L/dFLC >20 mg/L | 68 (53%)/98 (82%) |
| Lambda:kappa | 75 (61):47 (39) |
| Monoclonal component type | |
| IgG/IgM | 33 (27)/36 (29) |
| IgA/light chain only | 8 (6)/45 (38) |
| Bendamustine dosage | |
| 60 mg/m2 | 21 (17) |
| 70 mg/m2 | 11 (9) |
| 80 mg/m2 | 7 (6) |
| 90 mg/m2 | 29 (24) |
| 100 mg/m2 | 54 (44) |
ANS, autonomic nervous system; BeP, bendamustine and prednisone; dFLC, difference between involved and uninvolved free light chains; GI, gastrointestinal; PNS, peripheral nervous system.
In relapse/refractory patients.
Other treatments: 2 ixazomib; 2 cyclophosphamide, doxorubicin, vincristine, and prednisone; 1 vincristine, doxorubicin, and dexamethasone; 1 vincristine; 1 high-dose carmustine, etoposide, cytarabine, and melphalan therapy; 1 radiotherapy; 1 interferon; and 1 chlorambucil.
Other organs involved: 3 lymph nodes and 2 lung involvement.